Advanced searches left 3/3

Diltiazem - Crossref

Summarized by Plex Scholar
Last Updated: 20 August 2022

* If you want to update the article please login/register

Enalapril and diltiazem co-administration and respiratory side effects of enalapril.

The aim of this article was to track the correlation between the 15-day administration of enalapril and the defense reflexes of the airways in experimental animals, as well as the possibility of pharmacological limitation with simultaneous diltiazem administrations. An in vitro test in guinea pigs revealed that the reactivity of tracheal smooth muscles of the airways to bronchoconstrictor mediators was determined. The findings revealed that long-term administration of enalapril resulted in a significant rise in measured cough parameters and increased reactivity of tracheal smooth muscle to histamine and KCl. Enalapril-induced hyperreactivity of tracheal smooth muscle muscles to KCl, which was partially reduced by simultaneous administration of enalapril with diltiazem. The findings revealed a partially protective role of diltiazem and enalapril co-administration on respiratory adverse effects caused by enalapril therapy's respiratory adverse effects.

Source link: https://doi.org/10.33549/physiolres.930605


Diltiazem inhibits breast cancer metastasis via mediating growth differentiation factor 15 and epithelial-mesenchymal transition

Abstract Migrant and metastasis are both typical among triple-negative breast cancer patients with advanced disease. Cell motility is mediated by calcium channel blockers, according to Accumulating evidence. We found that using both mouse and human TNBC cell lines, diltiazem reduced colony formation and cell migration in breast cancer cells, which was shown by the authors. Moreover, treatment with diltiazem in tumor-bearing mice also reduces cancer metastasis and nodule formation, with more GDF-15 expression in diltiazem-treated mice than in saline-treated mice, respectively. These results show that diltiazem increases EMT and cell motility by raising GDF-15 expression in breast cancers both in vitro and in vivo.

Source link: https://doi.org/10.1038/s41389-022-00423-5


Amiloride and diltiazem inhibition of microsomal and mitochondrial Na+ and Ca2+ transport

In this paper, similar inhibitory effects of both agents are shown for Na+-induced Ca2+ release from rabbit heart mitochondria and Na+ uptake in a kidney medulla microsomal preparation. Both amiloride and diltiazem exhibit a 50% inhibition of Na+ uptake in kidney microsomes at the same dosages. Heart mitochondrial Na+-mediated Ca2+ production was halted by 6 microM diltiazem and 200 micro micrometer amiloride, with 50% reduced by 6 microM diltiazem and 200 microM amiloride. No effects of either agent on mitochondrial respiratory function were found.

Source link: https://doi.org/10.1152/ajpcell.1984.246.1.c172


Comparison of the Effects of Diltiazem Gel with Lidocaine Gel on Reducing Pain and Discomfort in Patients Undergoing Rectosigmoidoscopy: A Randomized Double-blinded Clinical Trial

The use of local lidocaine as an analgesic has no effect on pain relief in patients undergoing rectosigmoidoscopy, according to findings. The current study aims to compare the effects of diltiazem gel, an antispasmoic drug with local pain-reducing capabilities, with lidocaine gel in patients undergoing flexible rectosigmoidoscopy. After gaining the informed consent and being randomly assigned to one of the lidocaine gel or diltiazem gel groups ten minutes before rectosigmoidoscopy, a total of 80 patients who were potential candidates for rectosigmoidoscopy were enrolled in the study. According to the patients in the lidocaine and diltiazem groups, the mean VAS score for pain reported by the patients was 3. 97, 1. 89, and 2. 36 respectively. Despite no side effects, the use of local diltiazem gel around the anus can safely reduce the pain and discomfort in patients during rectosigmoidoscopy.

Source link: https://doi.org/10.2174/1574885516666210125112637


Convolution- and Deconvolution-Based Approaches for Prediction of Pharmacokinetic Parameters of Diltiazem Extended-Release Products in Flow-Through Cell Dissolution Tester

In vitro-in vivo correlation, the present study investigated the effect of different configuration configurations of the Flow-Through Cell dissolution tester in developing in vitrou2013in vivo correlation. According to the open- and closed loop configurations, respectively, 65% of labeled DTZ release from ER products was influenced by operating the FTC in various configuration-setups, where u2265 75% of labeled DTZ was released after 6 h and 12 h using the open- and closed-loop settings was released. With a minimal prediction error in comparison to the deconvolution-based strategy, the Convolution-based strategy was more precise in predicting DTZ in vivo PK parameters with little error. A successful trial to predict DTZ PKs from individual in vitro experiments developed in the USP IV dissolution model was carried out, using convolution technology. The convolution strategy's basic principle of the convolution approach provides a fast and cost-effective method for producing IVIVC, and it could be used for other BCS Class I extended-release drug products.

Source link: https://doi.org/10.1208/s12249-022-02361-2


Effect of diltiazem on experimental chronic cerebral vasospasm in the monkey

U2713 The effect of diltiazem on chronic cerebral vasospasm was investigated following subarachnoid hemorrhage in a primate model. Six monkeys were treated with diltiazem for two days before the hemorrhage was surgically developed and for five days after. The mean diameter of cerebral arteries measured at six angiographic locations was 60% of the pre-SAH diameter for the untreated group and 97 percent for the diltiazem-treated group. These experiments with this primate model of chronic cerebral vaping show that vascular narrowing and neurological dysfunction can be markedly reduced by diltiazem pretreatment.

Source link: https://doi.org/10.3171/jns.1985.62.6.0912


Effects of verapamil and diltiazem on acute stroke in cats

U2713 - U2713 To measure the effects of verapamil and diltiazem in acute stroke, three groups of mongrel cats of either gender underwent occlusion of the middle cerebral artery by a transorbital technique under ketamine anesthesia. Changes in SSEP's paralleled blood flow changes, with verapamil decreasing amplitude and conduction speed, while diltiazem slightly increased conduction in the ischemic brain, are shown in figure 6. Diltiazem-treated animals had decreased cerebral H 2 O content and the content of cerebral H 2 O, but there was a sharp rise in the area of nonperfused brain, but not in the area of nonperfused brain, a finding that is correlated with the heightened risk of transtentorial herniation in the diltiazem-treated animals. These findings support in vitro studies that demonstrate a high sensitivity of cerebral blood vessels to calcium channel blockers. These findings reveal that calcium channel blockers may have been involved in several classes of calcium channels, at various brain locations.

Source link: https://doi.org/10.3171/jns.1985.63.6.0929


Variability in Plasma Lipoprotein Profiles When Comparing Diltiazem and Propranolol

In a double-blind, comparative trial, we intend to investigate the effects of diltiazem and propranololol on plasma lipoproteins. RESULTS: No significant changes were observed in plasma lipoprotein concentrations in either the diltiazem or propranol group, or each other, in comparison to baseline values or each other. Following opioid therapy, differences in HDL, LDL, and VLDL were discovered in eight subjects whose lipoprotein levels were remeasured prior to drug therapy despite placebo. CONCLUSIONS: Changes in plasma lipoproteins seen as a result of antihypertensive therapy may only represent normal intrapatient variability.

Source link: https://doi.org/10.1177/106002809302700906


Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation

We compared the results of kidney function in patients with atrial fibrillation, concomitant use of diltiazem with DOACs and bleeding among patients with atrial fibrillation. During the follow-up to U2010, 15% patients were taking diltiazem at the time of DOAC's inception, and an additional 5% were started on diltiazem, and an additional 5% were initiated on diltiazem. Among DOAC patients using diltiazem simultaneously was elevated risk of any bleeding-related hospitalization, as well as major bleeding. Both patients with and without CKD were found with an elevated risk of any/major bleeding with diltiazem. Conclusions Concomitant use of diltiazem with DOACs has been correlated with a higher risk of atrial fibrillation in patients with atrial fibrillation, particularly in both subgroups of chronic kidney disease and non-chronic kidney disease.

Source link: https://doi.org/10.1161/jaha.122.025723

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions